Open company graph database — free web & API
Login

Stella Pharma Co., Ltd.

ステラファーマ株式会社STELLA PHARMA CORPORATIONAlias
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
47
Related companies
7
§01

Basic information

BASIC
Head office
3-2-7 Karasuma, Chuo-ku, Osaka, Osaka Prefecture, ORIX Karasuma Building
Chief executive
Kouji Uehara
Capital
3,000,000,000  (30 100 million)
Employees (non-consolidated)
44 people
Employees (consolidated)
47 people
Start date
2007-06-01
End date
§02

Websites

1 DOMAINS
§03

Business

2
Development of boron drugs used in BNCT (Boron Neutron Capture Therapy)Manufacturing and sales of boron drugs used in BNCT (Boron Neutron Capture Therapy)
§04

Related companies

7 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Stella Chemifa Corporation
Group
Sumitomo Heavy Industries, Ltd.
Group
INCJ Inc.
Group
株式会社産業革新機構(現株式会社INCJ)
Group
海南博鰲(ボアオ)楽城国際医療旅遊先行区
Group
独立行政法人科学技術振興機構(略称 JST)
Group
住友
Alliance
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

21 EVENTS

Established as a 100% subsidiary of Stella Chemifa Co., Ltd.Sources

Establishment.Sources

Obtained license for manufacturing and sales of type 1 pharmaceuticals (Osaka Prefecture).Sources

Initiated Phase I clinical trial of SPM-011 for brain tumors in Japan (target patients: recurrent malignant glioma).Sources

Initiated Phase I clinical trial of SPM-011 for brain tumors in Japan.Sources

Relocated the research laboratory to the Osaka Prefecture University BNCT Research Center to improve R&D efficiency (Sakai City, Naka-ku).Sources

Initiated Phase I clinical trial of SPM-011 for head and neck cancer in Japan (target patients: unresectable locally recurrent head and neck cancer and unresectable locally advanced head and neck cancer (non-squamous cell carcinoma)).Sources

Initiated Phase I clinical trial of SPM-011 for head and neck cancer in Japan.Sources

Initiated Phase II clinical trial of SPM-011 for brain tumors in Japan (target patients: recurrent malignant glioma).Sources

Initiated Phase II clinical trial of SPM-011 for brain tumors in Japan.Sources

Implemented capital increase through a third-party allotment with the Industrial Innovation Organization Inc. (now INCJ) and Sumitomo Heavy Industries as underwriters (Stella Chemifa's voting share decreased to 64%).Sources

Implemented capital increase through a third-party allotment with the Industrial Innovation Organization Inc. (now INCJ) and Sumitomo Heavy Industries as underwriters.Sources

Initiated Phase II clinical trial of SPM-011 for head and neck cancer in Japan (target patients: unresectable locally recurrent head and neck cancer and unresectable locally advanced head and neck cancer (non-squamous cell carcinoma)).Sources

Initiated Phase II clinical trial of SPM-011 for head and neck cancer in Japan.Sources

SPM-011 designated as a subject item (drug) under the Ministry of Health, Labour and Welfare's pioneering review designation system.Sources

Established Tokyo office (Chuo-ku, Tokyo).Sources

Obtained manufacturing and sales approval for BNCT drug Stereobulin® (SPM-011) with indication for 'unresectable locally advanced or locally recurrent head and neck cancer'.Sources

Obtained manufacturing and marketing approval for the BNCT drug steboronin (SPM-011) for the treatment of unresectable locally advanced or locally recurrent head and neck cancer.Sources

Commenced sales of BNCT drug Stereobulin®.Sources

Commenced sales of the BNCT drug steboronin.Sources

Listed on the Tokyo Stock Exchange Mothers market.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information5120001124194
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
ステラファーマ株式会社
Trade name (kana)
ステラファーマ
Name in English
Corporation type
301
Address
〒541-0043 大阪府大阪市中央区高麗橋3丁目2番7号ORIX高麗橋ビル
Postal code
5410043
Prefecture code
27
City code
128
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-07-20
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
4204231
METI gBizINFO5120001124194
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
5120001124194
Trade name
ステラファーマ株式会社
Trade name (kana)
ステラファーマ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
大阪府大阪市中央区高麗橋3丁目2番7号ORIX高麗橋ビル
Postal code
5410043
Prefecture
大阪府
Prefecture code
27
City or district
大阪市中央区
City code
128
Street address
高麗橋3丁目2番7号ORIX高麗橋ビル
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
代表取締役社長  上原 幸樹
Capital
2859218000
Employees
47
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-07-20
Key information
5120001124194
§09

Sources & updates

SOURCES
↑